Synexus Clinical Research US, Inc. - Phoenix Central ( Site 0030) — Phoenix, Arizona

Synexus Clinical Research US, Inc. - Phoenix Central ( Site 0030) is a clinical research site located in Phoenix, Arizona, United States 85020.

Crixeo Clinical Trials Trust Score: 9/100 (FAILING). This profile has not yet been claimed by the site owner.

Synexus Clinical Research US, Inc. - Phoenix Central ( Site 0030) has participated in 1 clinical trials with 1 currently active.

Therapeutic areas: Hyperlipidemia.

Sponsors: Merck Sharp & Dohme LLC.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Phoenix

Browse all research sites in Arizona · View every site in Phoenix

Sponsor Feasibility Report

Trust Score: 9/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Synexus Clinical Research US, Inc. - Phoenix Central ( Site 0030)?

Synexus Clinical Research US, Inc. - Phoenix Central ( Site 0030) has a Crixeo Trust Score of 9/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Synexus Clinical Research US, Inc. - Phoenix Central ( Site 0030) conducted?

Synexus Clinical Research US, Inc. - Phoenix Central ( Site 0030) has 1 clinical trials on record, with 1 currently active. Their work covers Hyperlipidemia.

Is Synexus Clinical Research US, Inc. - Phoenix Central ( Site 0030) accredited by Crixeo Clinical Trials?

Synexus Clinical Research US, Inc. - Phoenix Central ( Site 0030) has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Synexus Clinical Research US, Inc. - Phoenix Central ( Site 0030)?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.